Taken together, TCGA and IHC studies of human squamous cell tongue cancer support that LOXL2 is expressed at high levels in poorly differentiated and well-differentiated oral cancer by tumor cells and mesenchymal cells, and further support the notion that LOXL2 likely contributes to the etiology of metastatic disease. Here, LOXL2 is linked to lip and oral cavity carcinoma.